German HTA likely to toughen path for orphan drugs, warns industry association
This article was originally published in SRA
Executive Summary
Companies developing orphan drugs should prepare for changes to Germany's early benefit assessment system that could make staying on the market with a reasonable price tougher, warns the European Confederation of Pharmaceutical Entrepreneurs (Eucope)1.